• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Positive Impact of a Point-of-Care Molecular Influenza Test in the Emergency Department During the 2017-2018 Seasonal Influenza Epidemic

tetano

Editor, Senior Moderator
Open Forum Infect Dis. 2019 Jul 1;6(7). pii: ofz312. doi: 10.1093/ofid/ofz312.
[h=1]Positive Impact of a Point-of-Care Molecular Influenza Test in the Emergency Department During the 2017-2018 Seasonal Influenza Epidemic.[/h] Martinot M[SUP]1[/SUP], Greigert V[SUP]1,[/SUP][SUP]2[/SUP], Gravier S[SUP]1[/SUP], Klein S[SUP]1[/SUP], Eyriey M[SUP]3[/SUP], Pachart A[SUP]3[/SUP], Kaiser JD[SUP]4[/SUP], Zadeh MM[SUP]1[/SUP], De Briel D[SUP]5[/SUP], Gottwalles Y[SUP]6[/SUP], Thibaud E[SUP]6[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] During the 2017-2018 flu epidemic, the point-of-care Alere-i (n = 72) and reverse transcription polymerase chain reaction (n = 106) tests were compared. Patients in the point-of-care group were administered oseltamivir significantly more rapidly (9 hours vs 23 hours), they spent less time in the emergency department, and they had lower rates of antibiotic administration and hospitalization.
? The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.


[h=4]KEYWORDS:[/h] influenza; nucleic-acid amplification test; oseltamivir; point of care; seasonal flu

PMID: 31363768 DOI: 10.1093/ofid/ofz312
 
Back
Top Bottom